Filing Details
- Accession Number:
- 0001209191-18-011244
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2018-02-20 16:03:16
- Reporting Period:
- 2018-02-16
- Accepted Time:
- 2018-02-20 16:03:16
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1439222 | Agios Pharmaceuticals Inc | AGIO | Pharmaceutical Preparations (2834) | 000000000 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1608601 | Christopher Bowden | C/O Agios Pharmaceuticals, Inc. 88 Sidney Street Cambridge MA 02139 | Chief Medical Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2018-02-16 | 2,000 | $35.16 | 2,881 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2018-02-16 | 1,500 | $77.51 | 1,381 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2018-02-16 | 500 | $78.08 | 881 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock option (right to buy) | Disposition | 2018-02-16 | 2,000 | $0.00 | 2,000 | $35.16 |
| Common Stock | Stock option (right to buy) | Acquisiton | 2018-02-16 | 33,000 | $0.00 | 33,000 | $77.70 |
| Common Stock | Restricted stock units | Acquisiton | 2018-02-16 | 8,250 | $0.00 | 8,250 | $0.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 105,000 | 2024-05-30 | No | 4 | M | Direct | |
| 33,000 | 2028-02-15 | No | 4 | A | Direct | |
| 8,250 | No | 4 | A | Direct |
Footnotes
- This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $76.98 to $77.91. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $78.00 to $78.21. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- This option was granted on May 31, 2014. The shares underlying this option vest as to 25% of the underlying shares on May 13, 2015, with the remaining 75% vesting in 36 equal monthly installments thereafter.
- This option was granted on February 16, 2018. The shares underlying this option vest as to 25% of the underlying shares on February 16, 2019, with the remaining 75% vesting in 36 equal monthly installments thereafter.
- Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.
- The restricted stock units were granted on February 16, 2018. The shares underlying the restricted stock units will vest in three equal annual installments on February 16, 2019, 2020 and 2021. Vested shares will be delivered to the reporting person within three business days after such shares become vested.
Billionaire Hedge Funds
